Lead program to treat patients with GI Diseases & Disorders

Our lead program includes five drug candidates for GI therapeutics:

• SYGN305 for Radiation Mucositis and Radiation Proctitis
• SYGN399 for Radiation Syndrome
• SYGN313 for both acute and chronic inflammation of the GI tract, such as Crohn’s disease and inflammatory bowel disease (IBD)
• SYGN309 for GI Infection
• SYGN303 for distal intestinal obstructive syndrome (DIOS)

Synedgen is developing SYGN303 as a potential treatment for distal intestinal obstructive syndrome (DIOS), in which thick mucus causes blockage in the intestine. DIOS is a GI complication associated with cystic fibrosis, for which there are no targeted or approved drugs.